Ron Laufer is a newly designated Managing Director of Medlmmune Ventures, and the corporate arm of the AstraZeneca, a prominent pharmaceutical firm. It must be decided by Laufer whether to pursue a high potential, but really risky, early-stage investment. The decision Laufer will make will reflect his vision for MedImmune Ventures and more broadly the motivators he faces as a corporate venture capitalist.
PUBLICATION DATE: August 19, 2013 PRODUCT #: 814023-PDF-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
Mount Rundle Hotel Banff
Implementing Reverse E-Auctions: Learning Process
The Battle of the Asian Transshipment Hubs: PSversus PTP (B)
Note on Methodological Fit in Management Field Research
Succession and Continuity for Johnson Family Enterprises (A)
Vanity Fair Mills: Market Response System
Internationalization of Services Module Note
Rent the Runway (Abridged)
The Pelayo Family Plays Roulette: The Prequel
HSBC France: Re-Branding CCF (A)
